Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metab… Read more
Innovent Biologics Inc (IVBXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.022x
Based on the latest financial reports, Innovent Biologics Inc (IVBXF) has a cash flow conversion efficiency ratio of 0.022x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($313.76 Million) by net assets ($14.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Innovent Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Innovent Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Innovent Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innovent Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GEA GROUP
XETRA:G1A
|
0.222x |
|
Fresenius Medical Care AG & Co. KGaA
PINK:FMCQF
|
0.053x |
|
EDP - Energias de Portugal S.A
OTCGREY:ELCPF
|
0.051x |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
0.068x |
|
Aspeed Technology
TWO:5274
|
0.170x |
|
Avidity Biosciences, Inc
NASDAQ:RNAM
|
-0.101x |
|
Siemens Healthineers AG
PINK:SEMHF
|
0.025x |
|
Equitable Holdings Inc
F:AXJ
|
0.189x |
Annual Cash Flow Conversion Efficiency for Innovent Biologics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.12 Billion | $1.29 Billion | 0.098x | +731.56% |
| 2023-12-31 | $12.53 Billion | $147.81 Million | 0.012x | +106.60% |
| 2022-12-31 | $10.73 Billion | $-1.92 Billion | -0.179x | +8.77% |
| 2021-12-31 | $10.33 Billion | $-2.02 Billion | -0.196x | -459.30% |
| 2020-12-31 | $8.78 Billion | $-307.69 Million | -0.035x | +89.99% |
| 2019-12-31 | $4.76 Billion | $-1.66 Billion | -0.350x | -44.47% |
| 2018-12-31 | $4.19 Billion | $-1.02 Billion | -0.242x | -179.82% |
| 2017-12-31 | $-1.62 Billion | $-492.27 Million | 0.303x | -19.89% |
| 2016-12-31 | $-958.22 Million | $-362.99 Million | 0.379x | -- |